Anagram Therap 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   1 Trial   1 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SNSP-113 / Anagram Therap
2019-003178-25: A study of safety, tolerability and effect of SNSP113 in Cystic Fibrosis Az SNSP113 biztonságosságára, tolerálhatóságára és hatásosságára irányuló vizsgálat cisztás fibrózisban

Ongoing
2
56
Europe
SNSP113, SNSP113, Nebulisation solution
Synspira Therapeutics, Inc., Synspira Therapeutics, Inc.
Cystic Fibrosis, Cystic fibrosis (CF) is a life-threatening genetic disorder that results in the accumulation of thick, sticky mucus in the lungs, clogging airways and leading to infection and chronic inflammation., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ANG003 / Anagram Therap
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003

Completed
1
51
US
ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.
Anagram Therapeutics, Inc.
Exocrine Pancreatic Insufficiency
07/24
07/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SNSP-113 / Anagram Therap
2019-003178-25: A study of safety, tolerability and effect of SNSP113 in Cystic Fibrosis Az SNSP113 biztonságosságára, tolerálhatóságára és hatásosságára irányuló vizsgálat cisztás fibrózisban

Ongoing
2
56
Europe
SNSP113, SNSP113, Nebulisation solution
Synspira Therapeutics, Inc., Synspira Therapeutics, Inc.
Cystic Fibrosis, Cystic fibrosis (CF) is a life-threatening genetic disorder that results in the accumulation of thick, sticky mucus in the lungs, clogging airways and leading to infection and chronic inflammation., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ANG003 / Anagram Therap
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003

Completed
1
51
US
ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.
Anagram Therapeutics, Inc.
Exocrine Pancreatic Insufficiency
07/24
07/24

Download Options